Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LataMed AILMED -5.52%23 Equity-to-Asset is 0.90 as of Jun. 2026, which is 1% below its 10-year median of 0.91. GuruFocus rates LMED with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 2,891 Software companies, LataMed AI ranks better than 94.92% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. LataMed AI's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $7.05 Mil. LataMed AI's Total Assets for the quarter that ended in Jun. 2026 was $7.82 Mil.
The historical rank and industry rank for LataMed AI's Equity-to-Asset or its related term are showing as below:
LMED'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.9 Med: 0.91 Max: 0.91
Current: 0.9
During the past 3 years, the highest Equity to Asset Ratio of LataMed AI was 0.91. The lowest was 0.90. And the median was 0.91.
LMED's Equity-to-Asset is ranked better than 94.92% of 2891
companies
in the Software industry
Industry Median: 0.55
vs LMED: 0.90
LataMed AI (OTCPK:LMED) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
LataMed AI Equity-to-Asset Related Terms
LataMed AI Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for LataMed AI's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMED vs RYDE, RDZN, DMRC: Equity-to-Asset Comparison
For the Software - Application subindustry, LataMed AI's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LataMed AI Equity-to-Asset vs Software Industry
For the Software industry and Technology sector, LataMed AI's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where LataMed AI's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
LataMed AI's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LataMed AI (LMED) has a Equity-to-Asset of 0.90 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on LataMed AI and its competitors. This is near median its historical median of 0.91. Over the past decade, LataMed AI's Equity-to-Asset has ranged from 0.90 to 0.91. According to the industry distribution chart, LataMed AI ranks #147 out of 2891 companies in the Software industry, placing it in the top 5.1%.
Is LataMed AI's Equity-to-Asset too high?
LataMed AI's current Equity-to-Asset of 0.90 is near median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 0.91. The Software industry median Equity-to-Asset is 0.55. LataMed AI's value of 0.90 is 63.6% above this industry median. Based on the distribution chart, LataMed AI ranks #147 out of 2891 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, LataMed AI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does LataMed AI's Equity-to-Asset compare to RYDE and RDZN?
According to the Software industry distribution chart, LataMed AI ranks #147 out of 2891 companies for Equity-to-Asset. This places LataMed AI in the top 5% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.55. LataMed AI's value of 0.90 is 63.6% above this benchmark. Historically, LataMed AI's own Equity-to-Asset has ranged from 0.90 to 0.91 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.55, LataMed AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Software company?
The median Equity-to-Asset among Software companies is 0.55, based on 2,891 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LataMed AI's current Equity-to-Asset of 0.90 is 63.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on LataMed AI and its competitors. For the Software industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LataMed AI's current Equity-to-Asset is 0.90, which is near median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LataMed AI stock overvalued right now?
LataMed AI (LMED) has a current Equity-to-Asset of 0.90. The current Equity-to-Asset is 0.90, which is near median its 10-year median of 0.91 and 63.6% above the Software industry median of 0.55. LataMed AI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For LataMed AI (LMED), the current Equity-to-Asset is 0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America. Its healthcare platform includes AI-enabled analytics, telehealth infrastructure, and coordinated care systems designed to support healthcare delivery in emerging markets. The company develops digital infrastructure for patient prioritization, clinical workflow management, telehealth access, care coordination, and healthcare system operations. It holds issued patents for its core AI modules-CardioAI, PulmoAI, and NeuroAI-which deliver predictive analytics for cardiovascular, pulmonary, and neurological disease detection and management.
23GF Score
Get the complete analysis for LMED
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMED has been successfully added to your 
